Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 26

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 26
---
   2025  2024 Investment in equity securities with readily determined fair value (1):      Malaysia  -   863,810 Singapore  -   177,808   $-  $1,041,618          Investment in equity securities without readily determined fair value:        Malaysia  237,760   223,548   $237,760  $1,265,166  (1) The Company’s investment in equity securities is measured at fair value on a recurring basis. These equity securities are classified as Level 1 in the fair value hierarchy, as the fair value is determined using quoted market prices in active markets for identical assets. Specifically, the stock prices of these securities are readily available on the stock exchange, providing a reliable and observable input to the fair value measurement. As these securities are actively traded, the quoted prices in the market are considered to be the most reliable indicator of fair value. No significant adjustments are made to these prices, as they reflect current market conditions at the measurement date.

NOTE 8 - TRADE PAYABLES Trade payables are amounts billed to the Company by suppliers for goods and services in the ordinary course of business. All amounts have short-term repayment terms and vary by supplier.

 21Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

NOTE 9 – REVENUE  The following table shows disaggregated net revenue from contracts with customers by product or service line and geographic area for the quarter and nine month period ended September 30, 2025 and 2024:    Nine months ended   Three months ended    September 30,  September 30,  September 30,  September 30,   2025  2024  2025  2024 Revenue by product or service line:            Trading of industrial chemicals  6,929,849   6,975,567   2,539,055   2,627,813 Screening services and related sales  11,302   11,224   4,768